Clinical development of demethylating agents in hematology

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 40-46

  Navada, Shyamala C ^a   Steinmann, Juliane ^b   Lübbert, Michael ^b   Silverman, Lewis R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; ERYTHROPOIETIN; GEMTUZUMAB OZOGAMICIN; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHIMERA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DNA METHYLATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; ENGRAFTMENT; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENOMICS; HEMATOLOGY; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA; LEUKEMIA REMISSION; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84892915092     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69739     Document Type: Review

References (67)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-428
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692
3. Ley TJ, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982;307(24):1469-1475
4. Saunthararajah Y, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol. 2008;141(1):126-129
5. Olivieri NF, et al. A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood. 2011;118(10):2708-2711
6. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123(1):8-13
7. Silverman LR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(suppl 1):21-29
8. Silverman LR, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006; 24(24):3895-3903
9. Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440
10. Kornblith AB, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20(10):2441-2452
11. Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232
12. Silverman LR, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higherrisk myelodysplastic syndromes. Cancer. 2011; 117(12):2697-2702
13. List AF, et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission [abstract]. J Clin Oncol. 2008;26(15S):Abstract7006
14. Gore SD, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98(7):1067-1072
15. Najfeld V, Silverman LR, Scalise A, Lezon-Geyda K. Modulation of the cytogenetically abnormal myelodysplastic (MDS) clone by azacitidine (Aza C). Blood. 2002;100:97a.
16. Garcia-Manero G, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29(18):2521-2527
17. Rivard GE, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res. 1981; 5(6):453-462
18. Pinto A, et al. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant. 1989;4(suppl 3):28-32
19. Wijermans P, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18(5):956-962
20. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with highrisk myelodysplastic syndrome. Leukemia. 1997; 11(1):1-5
21. Lubbert M, et al. Cytogenetic responses in highrisk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol. 2001; 114(2):349-357
22. Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106(8):1794-1803
23. Kantarjian H, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higherrisk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57
24. Kantarjian HM, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109(2):265-273
25. Steensma DP, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842-3848
26. Iastrebner M, et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leuk Lymphoma. 2010; 51(12):2250-2257
27. Lubbert M, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987-1996
28. Braun T, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011; 118(14):3824-3831
29. Lee JH, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 2011;96(10):1441-1447
30. Fenaux P, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-569
31. Ravandi F, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009; 115(24):5746-5751
32. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561
33. Blum W, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16):7473-7478
34. Lubbert M, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012; 97(3):393-401
35. Kantarjian HM, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677
36. De Padua Silva L, et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009; 43(11):839-843
37. Lubbert M, et al. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant. 2009;44(9):585-588
38. Cogle CR, et al. Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol. 2010;8(1):40-46
39. Kim DY, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2012;47(3):374-379
40. Issa JP, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005; 23(17):3948-3956
41. Oki Y, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007; 109(5):899-906
42. Silverman LR, et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): A study of the New York Cancer Consortium. Blood. 2008;112(AML):1252.abstr3656
43. Platzbecker U, Germing U. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-A wise liaison? Leukemia. 2013;27(9):1813-1819
44. Sekeres MA, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher- risk myelodysplastic syndromes. Blood. 2012; 120(25):4945-4951
45. Blum W, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025-6031
46. Yang AS, et al. DNA methylation changes after 5-aza-2′- deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66(10):5495-5503
47. Fandy TE, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009; 114(13):2764-2773
48. Kantarjian HM, et al. Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in- Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. Paper presented at: ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, Georiga, USA.https://ash. confex.com/ash/2012/webprogram/Paper49626. html. Accessed November 18, 2013
49. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol. 2007; 35(2):263-273
50. Flotho C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009; 23(6):1019-1028
51. Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433
52. Walter MJ, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158
53. Challen GA, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012; 44(1):23-31
54. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843
55. Langemeijer SM, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842
56. Itzykson R, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147-1152
57. Green CL, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409-412
58. Bejar R, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506
59. Gore SD, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006; 66(12):6361-6369
60. Prebet T, et al. Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Presented at: 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, Califonia, USA;https://ash.confex. com/ash/2010/webprogram/Paper29350.html. Accessed November 18, 2013
61. Soriano AO, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110(7):2302-2308
62. Garcia-Manero G, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008; 112(4):981-989
63. Garcia-Manero G, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108(10):3271-3279
64. Kirschbaum M, et al. Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study. Paper presented at: 51st ASH Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Lousiana, USA. https://ash.confex.com/ash/2009/webprogram/Paper23454. html. Accessed November 18, 2013
65. Blum W, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25(25):3884-3891
66. Ravandi F, et al. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. Blood. 2007;110:897
67. Yee KWL, et al. A Phase I Trial of Two Sequence- Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML). Blood. 2007;110(3):908.